Dr. Gloria Gonzalez-Aseguinolaza holds a degree in Biological Sciences from the University of the Basque Country and a Ph.D. in Biochemistry and Molecular Biology from the Autonomous University of Madrid, Spain. After completing her doctorate, she conducted research for three and a half years at New York University, and in 2001, she joined the Center of Applied Medical Research (CIMA) at the University of Navarra where she is currently the director of the Gene therapy for Rare disease Program. In addition to this role, she has held various positions, including program director, head of the technology transfer office, and deputy director of CIMA. She founded a gene therapy company for rare diseases, Vivet Therapeutics, where she served as Scientific Director. She was the President of the Spanish Society for Gene and Cell Therapy (SETGyC) from 2019 until 2022 and is currently the secretary and board member of the European Society for Gene and Cell Therapy (ESGCT). She has published 155 papers and has presented over fifty invited lectures, including the educational programs of the European and American Societies for the study of the Liver and the European and American Societies of Gene and Cell Therapy. She has trained 22 Ph.D. students (7 more ongoing) and more than 40 national and foreign undergraduate, graduate and master students. She has received several awards, including the Rosalind Franklin Foundation Award for Research in 2023.